News

Public · Published

Tempus AI's Cancer Screen Business Drives Revenue Up 23%, While a Major Purchase Draws Closer — Barrons.com

Tempus AI reported third-quarter adjusted earnings of 7 cents a share, versus analysts' expected loss of 8 cents, while revenue rose 23% year over year to $411.5 million. Oncology testing volumes grew 32%, and tests for signs of cancer returning after treatment rose 300% to about 12,000. The company is moving toward completing its $1.5 billion purchase of Personalis.

Published:

Updated:

What happened

Tempus AI reported third-quarter adjusted earnings of 7 cents a share, versus analysts’ expected loss of 8 cents, while revenue rose 23% year over year to $411.5 million. Oncology testing volumes grew 32%, and tests for signs of cancer returning after treatment rose 300% to about 12,000. The company is moving toward completing its $1.5 billion purchase of Personalis.

Confirmed

Global impact / market context

Faster cancer-testing demand directly supports Tempus’s revenue growth, while improved earnings show the company exceeded analysts’ expectations for the quarter. Completing Personalis could expand its cancer-detection capabilities, but the purchase also requires substantial funding; the article gives no details on financing or expected financial benefits.

Analyst inference

Tempus’s results combine stronger testing volumes and revenue with progress toward a large acquisition, making execution important to the business outlook. The stock rose 3.9% in premarket trading after a 7.2% Friday decline, but remained about 26% below its October 2025 closing high.

Confirmed

What to watch

  1. Watch whether oncology testing volumes and revenue continue growing in later reports; sustained demand would support the operating growth shown this quarter. Analyst inference
  2. Watch for the completion of the proposed $1.5 billion Personalis acquisition and any disclosed funding terms, which could clarify its cash cost to Tempus. Proposed
  3. Watch whether Tempus reports continued growth in minimal residual disease testing, which detects possible cancer return after treatment and rose to about 12,000 tests. Analyst inference

Evidence

  • Original source link unavailable